The Nasdaq biotech index is down more than 20 percent since February, which has caused considerable anguish among the gamblers wooed into the high-risk field as stocks boomed last year. But some analysts are betting that the worst is over and that the correction has run its course. It's all in the fundamentals, insist some analysts. "You don't want to wait too long, (the selling) has been so dramatic it's worth looking into," Giri Cherukiri at OakBrook Investments tells Reuters. Of course, bull markets can't run forever. But it can seem like that at times. Story